Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

suring results from the Light Study may sufficiently characterize the cardiovascular risk of Empatic, so long as the weight loss and blood pressure and heart rate data for Empatic are similar to or more favorable than those of Contrave.  Orexigen owns worldwide rights to Empatic.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time)
The Orexigen management team will host a teleconference and webcast to discuss the third quarter 2012 financial results and recent business highlights. The live call may be accessed by phone by calling 888-895-5479 (US) or 847-619-6250 (International), participant code 33664518. The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... , July 29, 2014 Numotion,s Board of Directors ... Swinford will be the company,s new Chief Executive Officer. ... 22-year career at GE where he worked primarily for GE ... revenue to over $5 billion. His most recent position was ... "I am thrilled to join Numotion," said ...
(Date:7/29/2014)... , July 29, 2014  Roche (SIX: RO, ... Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo ... on the unique ways Roche is partnering with customers ... "Our customers tell us every day that they,re looking ... they deliver in their labs and offices," said ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... cells that multiply and migrate in the, embryo to ... a finding, that suggests that these cells might ... MEMPHIS, Tenn., Oct. 3 Investigators at St.,Jude Children,s ... the mammalian lymphatic vasculature -- the network of vessels ...
... Peptimmune, Inc. a privately,held biotechnology company, announced that ... trial to evaluate the safety, tolerability,pharmacokinetics and pharmacodynamics ... of multiple sclerosis and other autoimmune diseases. ... placebo controlled,randomized study will involve 56 healthy male ...
Cached Medicine Technology:St. Jude Settles Century-Old Debate on Origin of Mammalian Network of Lymphatic Vessels 2Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis 2
(Date:7/29/2014)... young children to embrace a more healthful diet? ... them. Doing so will actually make them think it ... and caregivers who are struggling to get children to ... food without saying anything about it, or (if credible) ... authors Michal Maimaran, of Northwestern University,s Kellogg School of ...
(Date:7/29/2014)... claims for cosmetic procedures using stem cells are running ... effectiveness, according to a review in the August issue ... the official medical journal of the American Society ... tremendous potential, but the marketplace is saturated with unsubstantiated ... risk," write Dr Michael T. Longaker of Stanford University ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
(Date:7/29/2014)... Nevada (PRWEB) July 29, 2014 The Board ... Holland & Hart LLP ’s Connie Akridge ... She currently serves as President of the Foundation. Akridge served ... , Akridge is a partner at Holland & Hart in ... litigation and regulatory/administrative matters to insurance and healthcare clients for ...
(Date:7/29/2014)... Many people complain about their dependence on eyeglasses. For ... put on glasses to see their clock or make their ... be dissatisfied with their vision even when using their glasses ... driving, especially at night due to glare. They can ... see the TV, sew or cross stitch, or read fine ...
Breaking Medicine News(10 mins):Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2
... home care which is advantageous for people with ... obstructive pulmonary disease (COPD) - can be very disabling, ... study from researchers at Barcelona// Hospital, Spain, shows that ... the home setting cuts costs, re-admission to hospital and ...
... a device that filters toxins from the blood can buy ... failure is a relatively common problem and most often the ... short supply and many patients die while waiting for one. ... many years now, but the liver is such a complex ...
... a new study, weight loss followed by weight gain is ... health risks of obesity are now well established to many. ... some studies have suggested that fluctuating weight may, in itself, ... ,Researchers in London studied a group of 5,428 middle-aged British ...
... cystitis depends upon how their condition is diagnosed according ... the bladder which leads to frequent urination,// incomplete emptying ... It's common among women and can greatly impair their ... University of Bergen, Norway, describes a new approach to ...
... a new research, people with severe respiratory disease can walk ... as they exercise. Exercise is key to pulmonary// rehabilitation in ... increase the distance they can walk in a fixed time ... ,Researchers at Ohio State University now report on ...
... regarding the do's and dont's of dieting. Nutrition experts at ... through the dieting controversy.// We've been discussing and arguing over ... - for many decades now, and still the obesity 'epidemic' ... Green Mountain in the US suggest a new approach - ...
Cached Medicine News:
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D...
... Sur-Catch NT stone retrieval basket raises proven tipless, ... unique paired wire design and multi-sizing basket enable ... of each patient and procedure. Its highly ... with the DURTM-8 Elite Ureteroscope and its ergonomic ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Medicine Products: